Retrospective secondary analysis of device data from 131 pivotal trial participants with central sleep apnoea: automatically activated transvenous phrenic nerve stimulation gave median nightly use of 5.7-6.0 h to 24 months, with 82-90% meeting adequate-use criteria.
Secondary analysisn = 131
Khayat et al. Automatic activation of neurostimulation for central sleep apnea results in high nightly usage